# Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo

> **NCT03249064** · — · COMPLETED · sponsor: **Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau** · enrollment: 28 (actual)

## Conditions studied

- VITILIGO

## Interventions

- **DIAGNOSTIC_TEST:** CD 91 levels
- **DIAGNOSTIC_TEST:** Tregs

## Key facts

- **NCT ID:** NCT03249064
- **Lead sponsor:** Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-27
- **Primary completion:** 2016-09-13
- **Final completion:** 2016-09-13
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03249064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03249064, "Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03249064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*